Assessing the impact of the CMS price transparency rule on patients with prostate cancer
Trials & Tribulations

Assessing the impact of the CMS price transparency rule on patients with prostate cancer

“It's the prices, stupid,” Uwe E. Reinhardt and authors famously wrote in their 2003 article describing the cause of high health care spending in the United States.1 Since then, multiple large analyses have confirmed that the prices of labor and goods, including pharmaceuticals and administrative costs, more so than differences in utilization, are the primary drivers of high health care spending.2,3
Against all odds – Unrelated stem cell transplants in coronavirus times
FreeTrials & Tribulations

Against all odds – Unrelated stem cell transplants in coronavirus times

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.The COVID-19 crisis has consequences not only for those who have become infected and the doctors and nurses who care for them. The care of other patients is also threatened by the increasing stress that national health systems and societies as a whole are under.